[FORM 8-K Filing Details](index=1&type=section&id=FORM%208-K%20Filing%20Details) This section outlines the basic identification and purpose of the Form 8-K filing for Aspira Women's Health Inc [General Information](index=1&type=section&id=General%20Information) This section provides the basic identification details for the Form 8-K filing, including the registrant's name, jurisdiction, commission file number, and principal executive offices - Registrant: **Aspira Women's Health Inc.**[1](index=1&type=chunk) - Date of Report (Date of earliest event reported): **November 14, 2024**[1](index=1&type=chunk) [Purpose of Filing](index=1&type=section&id=Purpose%20of%20Filing) The Form 8-K is filed to report selected financial results for the three and nine months ended September 30, 2024, which were announced via a press release - The filing is pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934[1](index=1&type=chunk) - The registrant is not an emerging growth company[2](index=2&type=chunk) [Item 2.02 Results of Operations and Financial Condition](index=1&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) This item reports the selected financial results for Aspira Women's Health Inc. for the three and nine months ended September 30, 2024 [Reporting of Selected Financial Results](index=1&type=section&id=Reporting%20of%20Selected%20Financial%20Results) Aspira Women's Health Inc. issued a press release on November 14, 2024, to report selected financial results for the three and nine months ended September 30, 2024. This press release is attached as Exhibit 99.1, and the information is furnished, not filed, under the Exchange Act - On **November 14, 2024**, Aspira Women's Health Inc. issued a press release reporting selected financial results[2](index=2&type=chunk) - The reported financial results are for the **three and nine months ended September 30, 2024**[2](index=2&type=chunk) - The press release is attached as **Exhibit 99.1** and is furnished, not deemed 'filed,' for purposes of Section 18 of the Securities Exchange Act of 1934[2](index=2&type=chunk)[3](index=3&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=3&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This item lists the exhibits accompanying the Form 8-K, including the press release and interactive data file [List of Exhibits](index=3&type=section&id=List%20of%20Exhibits) This section lists the documents furnished as exhibits to the Form 8-K, including the press release detailing financial results and the interactive data file for the cover page Exhibits to Form 8-K | Exhibit No. | Description | | :---------- | :--------------------------------------------------------------------------------------------------------------------------------------- | | 99.1 | Press Release issued by Aspira Women's Health Inc. on November 14, 2024 | | 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) | [Signatures](index=4&type=section&id=SIGNATURES) This section confirms the authorized signatory for the Form 8-K filing [Authorized Signatory](index=4&type=section&id=Authorized%20Signatory) The report was duly signed on behalf of Aspira Women's Health Inc. by its Interim Chief Financial Officer, John Kallassy, on November 14, 2024 - The report was signed by **John Kallassy**, Interim Chief Financial Officer[5](index=5&type=chunk) - Date of signature: **November 14, 2024**[5](index=5&type=chunk)

Achieved $141.6 million Net Revenue in Q3 2024Reported $25.1 million in Adjusted EBITDAAnticipates $30 million of Annual Savings Through Transformation InitiativesMORRISTOWN, N.J., Nov. 12, 2024 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," or the "Company" or "Ascend") (CSE: AAWH.U) (OTCQX: AAWH), a vertically integrated multi-state cannabis operator focused on bettering lives through cannabis, today reported its financial results for the three months ended September 30, 2024 ("Q3 2024"). Financial ...

AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Detai ...

AUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, has issued a letter to Company shareholders and announced it will host a virtual Research & Development Day on Tuesday, October 29, 2024, at 3:00 pm ET. The R&D Day will highlight the company’s plans for its miRNA development pipeline, including the recently announced award from the Advanced Res ...

AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health to address critical unmet challenges in women’s health, champion transformative innovations, and tackle health conditions that uniquely or disproportio ...

AUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has received approval from the New York State Department of Health’s (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) for OvaWatch®, the Company’s non-invasive blood test for the assessment of ovarian cancer risk for women with an adnexal mass determined by initial ...

Annex Insurance (AWH, Financial) stock recently experienced a sharp decline, dropping 7.47% to $0.761 per share. The trading volume stood at 16,266 shares, with a turnover rate of 0.10% and a price fluctuation of 2.62%.Recent financial reports show Annex Insurance faced significant challenges, recording a revenue of $2.42 million but a net loss of $3.53 million. Earnings per share were reported at -$0.28, with a gross profit of $1.42 million and a negative price-to-earnings ratio of -0.58. Currently, no ins ...

Aspira Womens Health (AWH, Financial) experienced a significant stock price drop of 7.80%, reaching $0.775 per share. The trading volume stood at 14,064 shares with a turnover rate of 0.09% and a volatility of 7.47%.Recent financial results for Aspira Womens Health revealed an operating revenue of $2.42 million and a net loss of $3.53 million, resulting in an earnings per share (EPS) of -$0.28. The gross profit was recorded at $1.42 million, with a price-to-earnings ratio of -0.57. Currently, no institution ...

Core Insights - Aspira Women's Health Inc. has entered a strategic partnership with Dorsata to develop a custom protocol workflow tool aimed at improving the management of adnexal masses [1][2] - The partnership seeks to standardize care and enhance patient outcomes by addressing the challenges in diagnosing and treating adnexal masses, which include ovarian cysts and other growths [2][3] - The integration of the new Module into Dorsata's electronic medical records system is expected to streamline diagnosis and treatment processes while aggregating clinical data for better analysis and outcomes [3] Company Developments - The Module's deployment is anticipated to begin by late 2024, marking a significant advancement in clinical practices for women's health [1] - Aspira's collaboration with over 250 obstetrics and gynecology physicians aims to ensure consistent care across various healthcare settings [2] - The partnership is expected to refine diagnostic and treatment protocols, potentially leading to early identification of ovarian cancer risks [3] Market Outlook - The global ovarian cancer treatment market is projected to grow from $2.50 billion in 2023 to $5.45 billion by 2033, reflecting an 8.10% CAGR [4][5] - Innovations in treatment, such as PARP inhibitors and anti-angiogenic therapies, are expected to enhance efficacy and drive market expansion [4][5] Share Performance - Aspira's shares have decreased by 74.8% year to date, contrasting with a 10% growth in the industry [6] - The company currently holds a Zacks Rank of 3 (Hold), indicating a cautious outlook compared to better-ranked stocks in the medical sector [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------|-------------------------------------------| | | | | For the transition | ______ | | Commission | 001-34810 | | As ...